title: Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction.
abstract: BACKGROUND
  Treatment with an angiotensin-converting enzyme (ACE) inhibitor benefits many patients with cardiovascular disease. ACE inhibitors are generally assumed to be equally effective, but this has never been fully verified in clinical trials.
  
  
  CONCLUSIONS
  Studying the association among ACE inhibitors after myocardial infarction demonstrated similarity in clinical outcome and supports a dosage-response relationship. Therefore, for long-term benefits for patients who need treatment with an ACE inhibitor, a focus of treatment at the recommended dosage is most important and not which ACE inhibitor is used.
  
  
  OBJECTIVE
  Therapy with angiotensin-converting enzyme (ACE) inhibitors is common after myocardial infarction (MI). Given the lack of randomized trials comparing different ACE inhibitors, the association among ACE inhibitors after MI in risk for mortality and reinfarction was studied.
  
  
  METHODS
  Patients hospitalized with first-time MI (n = 16,068) between 1995 and 2002, who survived at least 30 days after discharge and claimed at least one prescription of ACE inhibitor, were identified using nationwide administrative registries in Denmark.
  
  
  RESULTS
  Adjusted Cox regression analysis demonstrated no differences in risk for all-cause mortality, but patients using captopril had higher risk of reinfarction (hazard ratio 1.18, 95% confidence interval 1.05, 1.34). However, following adjustment for differences in used dosages, all ACE inhibitors had similar clinical efficacy. Risk of all-cause mortality: trandolapril (reference) 1.00, ramipril 0.97 (0.89, 1.05), enalapril 1.04 (0.95, 1.150), captopril 0.95 (0.83, 1.08), perindopril 0.98 (0.84, 1.15) and other ACE inhibitors or angiotensin II receptor blockers (ARB) 1.06 (0.94, 1.19). Reinfarction: trandolapril (reference) 1.00, ramipril 0.98 (0.89, 1.08), enalapril 1.04 (0.92, 1.17), captopril 1.05 (0.89, 1.25), perindopril 0.96 (0.81, 1.14) and other ACE inhibitors or ARB 0.99 (0.86, 1.14). Furthermore, the association between ARBs and clinical events was similar to ACE inhibitors (trandolapril reference): all-cause mortality 0.99 (0.84, 1.16) and recurrent MI 0.99 (0.83, 1.19).
  
  
  CONCLUSIONS
  Our results suggest a class effect among ACE inhibitors when used in comparable dosages. Focus on treatment at the recommended dosage is therefore most important, and not which ACE inhibitor is used.
authors: Department of Cardiovascular Medicine, Bispebjerg University Hospital, Copenhagen, Denmark. mlh@heart.dk
authors: Morten L
authors: ML
authors: Hansen
authors: Gunnar H
authors: GH
authors: Gislason
authors: Lars
authors: L
authors: Køber
authors: Tina Ken
authors: TK
authors: Schramm
authors: Fredrik
authors: F
authors: Folke
authors: Pernille
authors: P
authors: Buch
authors: Steen Z
authors: SZ
authors: Abildstrom
authors: Mette
authors: M
authors: Madsen
authors: Søren
authors: S
authors: Rasmussen
authors: Christian
authors: C
authors: Torp-Pedersen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000201:enzymology* / Q000401:mortality; D012042:Registries
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors
references: N Engl J Med. 1992 Sep 3;327(10):669-77
references: 1386652
references: Eur Heart J. 2006 May;27(10):1153-8
references: 16399775
references: Lancet. 1993 Oct 2;342(8875):821-8
references: 8104270
references: Lancet. 1994 May 7;343(8906):1115-22
references: 7910229
references: Am J Cardiol. 1994 Jun 15;73(16):1180-6
references: 8203335
references: Lancet. 1995 Mar 18;345(8951):669-85
references: 7661937
references: Lancet. 1995 Mar 18;345(8951):686-7
references: 7885123
references: N Engl J Med. 1995 Dec 21;333(25):1670-6
references: 7477219
references: J Clin Epidemiol. 1997 Jan;50(1):105-16
references: 9048695
references: Br J Clin Pharmacol. 1997 Apr;43(4):429-33
references: 9146856
references: Dan Med Bull. 1997 Sep;44(4):445-8
references: 9377907
references: Circulation. 1999 Dec 7;100(23):2312-8
references: 10587334
references: N Engl J Med. 2000 Jan 20;342(3):145-53
references: 10639539
references: Lancet. 2000 May 6;355(9215):1575-81
references: 10821360
references: Lancet. 2000 May 6;355(9215):1582-7
references: 10821361
references: Arch Intern Med. 2001 Jan 22;161(2):183-8
references: 11176731
references: Lancet. 2002 Sep 7;360(9335):752-60
references: 12241832
references: Pharmacoeconomics. 2003;21(2):89-103
references: 12515571
references: Eur Heart J. 2003 Jan;24(1):28-66
references: 12559937
references: J Clin Epidemiol. 2003 Feb;56(2):124-30
references: 12654406
references: Lancet. 2003 Sep 6;362(9386):782-8
references: 13678872
references: N Engl J Med. 2003 Nov 13;349(20):1893-906
references: 14610160
references: Ann Intern Med. 2004 Jul 20;141(2):102-12
references: 15262665
references: Eur Heart J. 2004 Aug;25(16):1454-70
references: 15302105
references: N Engl J Med. 1991 Aug 1;325(5):293-302
references: 2057034
references: N Engl J Med. 1991 Aug 1;325(5):303-10
references: 2057035
references: N Engl J Med. 2004 Nov 11;351(20):2058-68
references: 15531767
references: Am J Cardiol. 2005 Jan 15;95(2):283-6
references: 15642572
references: Eur Heart J. 2005 May;26(10):990-5
references: 15618048
references: Scand Cardiovasc J. 2005 Apr;39(1-2):42-9
references: 16097413
references: Med Care. 2005 Oct;43(10):970-8
references: 16166866
references: Eur Heart J. 2006 Apr;27(7):796-801
references: 16497685
references: Lancet. 1993 Mar 27;341(8848):829
references: 8096029